Infection progression depends on host-pathogen interactions that involve reversible lipid-modifications of host and microbial proteins by S-acylation. Targeting the dynamics of this modification, specifically deacylation diminishes bacterial toxin pathogenic mechanisms and viral infections. Our project is to expand our preclinical studies by developing and testing derivatives of anti-deacylation drugs for their increased potency as anti-viral and anti-toxin agents.